# US Psoriasis Treatment Market

> 美国银屑病治疗市场研究报告：按治疗类型（外用治疗、系统治疗、光疗、生物制剂）、给药途径（口服、外用、注射、静脉）、适应症（斑块型银屑病、滴状银屑病、反向银屑病、脓疱型银屑病）和最终用户（医院、皮肤科诊所、居家护理） - 增长前景与行业预测2025至2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.43%
- **2024:** $ 1,564.5 Million
- **2025:** $ 1,633.81 Million
- **2035:** $ 2,520 Million
- **Key Players:** AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Regeneron Pharmaceuticals (US), UCB (BE)

**Report ID:** MRFR/Pharma/14300-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-psoriasis-treatment-market-15827

---

## Market Summary

## **US Psoriasis Treatment Market Overview**

As per MRFR analysis, the US Psoriasis Treatment Market Size was estimated at 1.62 (USD Billion) in 2023. The US Psoriasis Treatment Market Industry is expected to grow from 1.79 (USD Billion) in 2024 to 2.98 (USD Billion) by 2035. The US Psoriasis Treatment Market CAGR (growth rate) is expected to be around 4.743% during the forecast period (2025 - 2035).

### **Key US Psoriasis Treatment Market Trends Highlighted**

The US Psoriasis Treatment Market is witnessing significant trends driven by increased awareness of psoriasis and its treatments. Patients are becoming more informed about their options, encouraging demand for effective therapies. The growing prevalence of psoriasis in the US, attributed to factors such as obesity, smoking, and stress, propels the market forward. There is a notable shift towards biologic therapies, which provide targeted treatment methods for moderate to severe cases. These advancements in precision medicine are replacing traditional treatments, providing better efficacy and fewer side effects.

The rise of telemedicine has also changed how patients access care, allowing for easier consultations with dermatologists, which is particularly beneficial for those in remote areas or with mobility challenges.

Opportunities within this market include the development of personalized medicine, combining genetic research and new treatment modalities tailored to individual patient needs. Additionally, guided patient education and support programs have opened avenues for pharmaceutical companies to engage with patients, improve treatment adherence, and enhance quality of life. Recent trends indicate an increased focus on combination therapies, where multiple treatments are used together to achieve better management of the condition. Moreover, ongoing research and innovations continue to emerge, with new drug candidates entering clinical trials that may enhance treatment effectiveness and safety.

This is particularly pertinent in the US, where regulatory pathways are advancing rapidly, reflecting a supportive environment for the introduction of innovative therapies. Overall, the US Psoriasis Treatment Market is on an upward trajectory, driven by both patient demand and the continuous evolution of treatment options.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Psoriasis Treatment Market Drivers**

### **Rising Incidence of Psoriasis**

The increasing prevalence of psoriasis in the United States is a significant driver for the US Psoriasis Treatment Market Industry. According to data from the National Psoriasis Foundation, an estimated 7.5 million Americans are living with psoriasis, which is roughly 2-3% of the U.S. population. This increasing prevalence leads to greater demand for effective treatments, driving market growth. The population's awareness regarding skin diseases has also surged, resulting in a higher rate of diagnoses and subsequent treatment initiation.

This trend is further supported by the development of innovative therapies. For example, companies such as Amgen and Johnson & Johnson have launched biologics that are transforming treatment paradigms, making psoriasis management more effective and tailored, thus expanding the patient base seeking treatment.

### **Advancements in Treatment Options**

Innovative therapies and advancements in treatment options can significantly propel the US Psoriasis Treatment Market Industry. The introduction of biologics and targeted therapies has changed the approach to managing psoriasis, leading to higher efficiency and better patient outcomes. The American Academy of Dermatology notes that biologic treatments have undergone rapid development over the past few years, with multiple new products being approved by the U.S. Food and Drug Administration. This not only increases competition among pharmaceutical companies but also provides healthcare providers with an expanded toolkit to manage psoriasis.

As a result, the availability of diverse treatment options is expected to grow, appealing to a wider range of patients and contributing to market growth.

### **Increased Patient Awareness and Education**

Rising patient awareness regarding psoriasis and its treatments is increasingly driving the US Psoriasis Treatment Market Industry. Various awareness campaigns conducted by organizations such as the National Psoriasis Foundation and American Academy of Dermatology focus on educating the public about skin health and the importance of seeking treatment. As more individuals recognize the symptoms and impact of psoriasis on their quality of life, they are more likely to seek medical attention.

A survey indicates that awareness regarding psoriasis has improved by nearly 35% among the general population over the past five years, which is pivotal in aiding early diagnosis and facilitating appropriate treatment pathways.

### **Growing Investment in Healthcare Infrastructure**

The growth of investment in healthcare infrastructure is also a vital driver for the US Psoriasis Treatment Market Industry. According to the Centers for Medicare and Medicaid Services, the U.S. healthcare spending is projected to grow at an average rate of 5.4% per year, reaching a substantial part of the GDP. This surge provides healthcare providers with improved resources, technologies, and facilities to manage and treat psoriasis effectively. Improved access to dermatology specialists and treatment centers translates into more patients receiving timely care.

Furthermore, robust investment in Research and Development by companies like Pfizer and AbbVie enhances the overall medication pipeline, driving better treatment options and improved patient outcomes.

## **US Psoriasis Treatment Market Segment Insights**

### **Psoriasis Treatment Market Treatment Type Insights**

The Treatment Type segment within the US Psoriasis Treatment Market encompasses a diverse range of therapeutic options aimed at addressing this chronic skin condition that affects millions in the United States. Topical Treatments, which are often the first line of defense, play a crucial role in managing symptoms by applying medications directly to the skin, thereby providing targeted relief for localized areas. Systemic Treatments are employed for more severe cases, offering comprehensive management through medications that work throughout the body, appealing particularly to individuals with widespread psoriasis or those unresponsive to topical therapies.

Phototherapy utilizes specific wavelengths of light to treat psoriasis effectively; this option not only serves as a critical alternative for many patients but is also endorsed for its potential to minimize systemic exposure to pharmaceuticals.

The increasing popularity of Biologics represents a significant shift in the market as they specifically target immune responses involved in psoriasis development, showcasing advanced mechanisms of action that help improve the quality of life for those affected. Overall, each treatment type contributes uniquely to the dynamic landscape of the US Psoriasis Treatment Market, responding to the varying needs of patients while highlighting ongoing advancements in dermatological therapies. The increasing awareness regarding treatment options, accompanied by the ongoing Research and Development in this sector, drives market growth and encourages patients and healthcare providers alike to explore these effective solutions.

As the treatment modalities evolve, understanding the nuances of each type continues to be pivotal for stakeholders in optimizing approaches for managing psoriasis, ultimately aiming to enhance patient outcomes and quality of life.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Psoriasis Treatment Market Administration Route Insights**

The US [Psoriasis Treatment](../../../reports/psoriasis-treatment-market-2769) Market has seen significant developments in its Administration Route segment, reflecting various approaches to patient care. This segment highlights the diverse methods available for delivering treatments, including Oral, Topical, Injectable, and Intravenous routes. Topical treatments are prominently used due to their localized effect, providing relief with minimal systemic exposure, and are often preferred for mild to moderate cases. In contrast, Injectable therapies have gained traction, especially with the advent of biologics, which target specific pathways in the immune response associated with psoriasis, offering more effective outcomes for severe cases.

Intravenous administration, although less common, plays a vital role in providing rapid treatment for patients needing immediate relief. Oral therapies remain popular as they offer convenience and ease of use, appealing to a broad patient base. These varied administration routes not only cater to the diverse needs of patients but also adapt to evolving treatment paradigms in the US, thereby enhancing overall treatment adherence and effectiveness. The continuous introduction of novel therapies through these routes reflects ongoing Research and Development efforts aimed at improving patient outcomes in the management of psoriasis.

### **Psoriasis Treatment Market Indication Insights**

The US Psoriasis Treatment Market is characterized by various indications that highlight the diverse needs of patients suffering from this chronic skin condition. Among these indications, Plaque Psoriasis is particularly significant, as it affects the majority of psoriasis patients with well-defined, raised lesions. Guttate Psoriasis, often triggered by infections, presents a different challenge and is more common in children and young adults, emphasizing the need for age-appropriate treatments.

Inverse Psoriasis, which occurs in skin folds, can be challenging to manage due to its sensitivity and the discomfort it causes, while Pustular Psoriasis, although less common, requires effective intervention due to the potential severity of symptoms.

The distinctions among these indications lead to differing treatment approaches, thereby influencing the US Psoriasis Treatment Market segmentation. This variability within the indication segment is crucial as it informs healthcare providers and pharmaceutical companies about the specific requirements for effective management of psoriasis, thereby driving innovation and developments in treatment therapies tailored for each type.

### **Psoriasis Treatment Market End User Insights**

The End User segment of the US Psoriasis Treatment Market includes hospitals, dermatology clinics, and homecare settings, each playing a vital role in the management and treatment of psoriasis. Hospitals signify a substantial portion of the market, equipped with advanced facilities and specialists that offer comprehensive care for severe cases. Dermatology clinics focus particularly on skin-related conditions, providing targeted therapies and support, making them a preferred choice for patients seeking specialized attention. Homecare settings are becoming increasingly significant, enabling patients to manage their treatment in the comfort of their homes, which is important for those seeking convenience and personalized care.

The rise in the prevalence of psoriasis in the United States, along with increasing awareness about treatment options and the growing demand for tailored therapies, fuel the growth of these segments. Moreover, the integration of telehealth services is enhancing accessibility in dermatology clinics and homecare settings, making it easier for patients to receive ongoing medical advice. This diverse segmentation highlights the various pathways of care available to individuals suffering from psoriasis, illustrating the evolving landscape of treatment options in the US Psoriasis Treatment Market.

## **US Psoriasis Treatment Market Key Players and Competitive Insights**

The US Psoriasis Treatment Market is characterized by intense competition, driven by a rising prevalence of psoriasis among the population, awareness regarding treatment options, and advancements in therapeutic technologies. This market includes a diverse range of treatment modalities, including biologics, systemic therapies, and topical treatments, which cater to different severity levels and patient preferences. As research and development continue to innovate in this space, various pharmaceutical companies are striving to secure their positions through strategic collaborations, product launches, and expanding their portfolios.

The landscape is also influenced by regulatory frameworks, pricing strategies, and the burgeoning demand for tailored therapies to enhance patient outcomes. All these factors play a vital role in shaping the competitive dynamics of the market.

Celgene holds a notable position within the US Psoriasis Treatment Market, particularly recognized for its commitment to developing innovative therapies that address the unmet needs of psoriasis patients. The company's strength lies in its robust pipeline, which includes several biologics that demonstrate significant efficacy in treating moderate to severe psoriasis. This focus on research and development has positioned Celgene as a formidable player in the market, allowing it to leverage its existing product portfolio and expand its therapeutic options.

Furthermore, Celgene's strong sales and marketing strategies enhance its visibility among healthcare professionals, while its commitment to patient support programs underscores its dedication to improving treatment adherence and patient satisfaction in the US region.

Novartis is another key competitor in the US Psoriasis Treatment Market, with a strong emphasis on developing integrated treatment solutions that cater to diverse patient needs. The company is known for its leading products that have become go-to options for the management of psoriasis. Novartis has strategically expanded its market presence through a series of mergers and acquisitions, which have significantly bolstered its portfolio of psoriasis therapies. Their investments in innovative therapies, including biologics and targeted therapies, have established Novartis as a market leader.

Additionally, Novartis focuses on patient-centric approaches, ensuring that its offerings not only meet clinical efficacy but also improve overall quality of life for individuals suffering from psoriasis. The company's robust distribution network further amplifies its reach within the US market, contributing to its competitive stance in the rapidly evolving landscape of psoriasis treatments.

### **Key Companies in the US Psoriasis Treatment Market Include**

## **US Psoriasis Treatment Market Industry Developments**

In recent developments within the US Psoriasis Treatment Market, significant advancements have been made by major players such as Novartis and AbbVie, launching upgraded formulations that have shown improved efficacy in clinical trials. For example, AbbVie's drug Humira continues to dominate the market while new entrants are closely following. Moreover, in September 2023, Regeneron Pharmaceuticals announced a strategic partnership with Sanofi to enhance the delivery of their eczema and psoriasis therapies, showcasing collaboration among leading firms.

Current affairs reflect a growing consumer demand for personalized medicine, prompting companies like Eli Lilly and Amgen to invest heavily in Research and Development for biologic treatments.

In merger and acquisition news, Bristol Myers Squibb completed its acquisition of Myokardia in October 2023, aimed at expanding its cardiovascular portfolio, which may indirectly impact its psoriasis product strategy. Market valuation has steadily grown, with the US Psoriasis Treatment Market estimated to reach $12 billion by 2025, primarily driven by innovative drugs and increasing prevalence rates as reported by the Centers for Disease Control and Prevention (CDC). Such growth highlights an evolving landscape with promising opportunities for both established companies and newcomers entering the psoriasis treatment sector.

## **US Psoriasis Treatment Market Segmentation Insights**

### **Psoriasis Treatment Market Treatment Type Outlook**

### **Psoriasis Treatment Market Administration Route Outlook**

### **Psoriasis Treatment Market Indication Outlook**

### **Psoriasis Treatment Market End User Outlook**

## Market Drivers

### Rising Healthcare Expenditure

美国不断增加的医疗支出是银屑病治疗市场的重要驱动因素。随着医疗支出的持续上升，患者更有可能寻求治疗银屑病等慢性疾病。到2025年，医疗支出预计将达到约4万亿美元，这表明人们在健康和保健方面的投资意愿不断增强。这一趋势可能导致对银屑病治疗的需求增加，因为患者优先考虑有效管理他们的病情。此外，针对先进疗法的保险覆盖正在改善，使治疗对更广泛的人群变得更加可及。因此，随着更多个人寻求有效的病情管理方案，银屑病治疗市场预计将扩大。

### Growing Prevalence of Psoriasis

美国银屑病的日益普遍是银屑病治疗市场的主要驱动因素。最近的估计表明，美国约有750万人受到这种慢性皮肤病的影响。患者数量的增加需要相应增加治疗选择，从而扩大市场。随着医疗服务提供者寻求满足这一不断扩大的患者群体的需求，银屑病治疗市场可能会经历增长。此外，疾病的慢性特性使得对有效疗法的需求加大，这通常需要长期管理。随着对银屑病的认识不断提高，市场可能会向更具创新性和个性化的治疗方案转变。

### Advancements in Treatment Modalities

治疗方式的创新正在显著影响银屑病治疗市场。新疗法的引入，包括生物制剂和靶向疗法，已经改变了银屑病管理的格局。例如，生物制剂在某些患者中的有效率高达90%，这比传统治疗有了显著改善。这一进展不仅提高了患者的治疗效果，还推动了市场增长，因为医疗服务提供者越来越多地采用这些新疗法。此外，结合不同治疗方法的组合疗法的发展可能进一步扩大患者可用的选择。随着市场的发展，个性化医学的关注可能会更加明显，以满足患有银屑病的个体的独特需求。

### Regulatory Support for New Treatments

对新治疗的批准的监管支持是银屑病治疗市场的一个关键驱动因素。美国食品药品监督管理局（FDA）已简化了创新疗法的批准流程，这鼓励制药公司投资开发新的银屑病治疗。这一监管环境可能会促进新疗法的引入，以满足银屑病人群未满足的医疗需求。随着新治疗获得加速批准，市场可能会见证患者可用选项的激增。此外，FDA对以患者为中心的方法的承诺可能会导致开发出不仅有效而且改善银屑病患者生活质量的疗法。

### Increased Investment in Dermatology Research

银屑病治疗市场受益于对皮肤病研究的投资增加。制药公司和研究机构正在分配大量资源来开发新疗法和改善现有疗法。预计到2025年，皮肤病领域的投资将增加约15%，反映出对银屑病作为重大公共卫生问题的日益认识。这一资金的涌入可能会加速创新的步伐，导致更多有效治疗选择的引入。此外，学术界与行业之间的合作正在促进银屑病研究突破的良好环境。因此，市场有望扩大，推动力来自于对改善治疗方案的持续追求。

## Future Outlook

预计银屑病治疗市场将在2025至2035年间以4.43%的年均增长率增长，推动因素包括生物制剂的进步、意识的提高和医疗支出的增加。

到2035年，银屑病治疗市场预计将实现显著增长和创新。

## Segment Insights

### 按类型：生物制剂（最大）与局部治疗（增长最快）

在美国银屑病治疗市场中，按类型划分的细分显示生物制剂继续以最大的市场份额占据主导地位。这归因于它们的有效性和银屑病病例的日益增加。尽管局部治疗历史悠久，但在系统性和[生物制剂](../../../reports/orthobiologics-market-7826)疗法的创新面前，局部治疗的增长速度被超越，但由于其可及性和易用性，它们仍占据市场的显著部分。近年来，美国银屑病治疗市场的增长趋势已转向生物制剂，因为患者越来越倾向于选择更具针对性的治疗方案。对皮肤病的认识提高以及治疗选择的进步推动了对系统性治疗和生物制剂的需求。此外，这些疗法提供的便利性和快速效果正在影响患者的选择和治疗计划，确保了局部治疗的竞争格局。

生物制剂（主导）与局部治疗（新兴）

生物制剂在银屑病治疗市场中占据主导地位，提供针对特定免疫通路的先进解决方案，这些通路与银屑病的爆发有关。它们的临床有效性和量身定制的方法解决了该病的严重形式，使其成为医疗专业人员和患者的首选。相比之下，局部治疗虽然是新兴的，但由于其较低的成本和易于应用，仍然是轻度至中度银屑病的重要选择。患者通常会先使用局部药物，然后在更严重的情况下转向生物制剂。这两个细分市场突显了治疗银屑病的多样选择，满足不同患者的需求和状况。

### 按给药途径：口服（最大）与注射（增长最快）

银屑病治疗的给药途径市场分布显示，口服细分市场占据最大份额，主要得益于其易用性和患者偏好。局部治疗也保持着显著的存在，常用于局部治疗。同时，注射选项正在获得关注，显示出患者对有效管理其病情的日益响应。增长趋势表明，注射治疗是增长最快的细分市场，这归因于生物制剂和靶向疗法的进步。随着越来越多的患者寻求有效和快速缓解银屑病症状，创新的注射药物配方变得颇具吸引力。此外，意识的提高和更好的诊断率也促进了各种给药途径的日益采用，进一步推动了市场扩张。

口服（主导）与注射（新兴）

口服给药途径在治疗领域中占据主导地位，因其便利性和患者的依从性。口服药物因其实用性而受到青睐，使患者能够在不需要注射的情况下管理他们的银屑病。相比之下，注射治疗正在迅速崛起，提供针对疾病进展中特定通路的生物制剂。随着医疗提供者将重点转向个性化医疗，预计注射药物将提高疗效和患者满意度。这两个细分市场满足不同患者的需求，口服治疗在成熟市场中领先，而注射治疗则为银屑病管理的未来增长和创新铺平了道路。

### 按适应症：斑块型银屑病（最大）与点滴型银屑病（增长最快）

在美国银屑病治疗市场的不同适应症中，斑块型银屑病占据最大的市场份额，占总数的绝大多数。这个细分市场因其慢性特性和对患者的重大负担而长期受到认可，促成了其主导地位。另一方面，点滴型银屑病作为增长最快的细分市场，因其更急性表现和多样的治疗选择而越来越吸引消费者。增长趋势表明，对不同类型银屑病的意识和治疗可用性都在上升，斑块型银屑病始终保持强劲。然而，点滴型银屑病病例的快速增加，尤其是在年轻人群中，推动了其增长。治疗选择的创新和对意识宣传的投资增加是推动美国银屑病治疗市场扩张的催化剂。

斑块型银屑病（主导）与点滴型银屑病（新兴）

斑块型银屑病，作为主导细分市场，其特征是慢性斑块，可能会显著影响生活质量。患者通常需要长期护理，导致对局部治疗、光疗和系统性选择的持续需求。该适应症的成熟性质确保了稳定的市场存在。相反，点滴型银屑病被标记为新兴细分市场，主要影响年轻个体，通常由感染引发。其表现为小的、滴状的病变，允许多样的管理方法和不断增长的消费者基础。随着意识和治疗可及性的改善，点滴型银屑病有望实现显著增长，吸引寻求有效和即时干预的群体。

### 按最终用户：医院（最大）与皮肤科诊所（增长最快）

美国银屑病治疗市场在各种最终用户中展示了多样的分布，医院因其提供全面护理和先进治疗选择的能力而占据最大份额。皮肤科诊所也代表了一个重要细分市场，吸引寻求针对其特定需求的专业护理的患者，使其在这一领域成为强有力的竞争者。增长趋势表明，皮肤科诊所是增长最快的细分市场，因为患者越来越倾向于选择针对性的治疗和个性化服务。这一转变是由银屑病的流行率上升和对专业皮肤科护理的需求增加所驱动的。此外，治疗方式的创新和医疗提供者意识的提高进一步增强了这些诊所的地位，预计它们将在未来市场动态中发挥关键作用。

医院（主导）与皮肤科诊所（新兴）

医院在美国银屑病治疗市场中仍然是主导的最终用户，利用其广泛的资源和多学科团队有效管理复杂病例。它们已建立了促进患者护理的协议，从而提高了患者保留率。相比之下，皮肤科诊所作为关键参与者正在崛起，提供针对银屑病患者的集中和专业治疗方案。个性化的方法和更短的等待时间提高了患者满意度，使这些诊所成为一个有吸引力的选择。此外，向门诊治疗选项的趋势对皮肤科诊所有利，可能会增加它们的市场份额，并为未来的增长铺平道路，因为越来越多的患者寻求便利和可及的护理。

## Competitive Benchmarking

银屑病治疗市场的特点是动态的竞争格局，由创新、战略合作伙伴关系和以患者为中心的解决方案的结合驱动。主要参与者如AbbVie（美国）、Amgen（美国）和Bristol-Myers Squibb（美国）通过其强大的产品组合和对研发的承诺，积极塑造市场。AbbVie（美国）继续利用其领先地位，成功推出新配方，而Amgen（美国）则强调其对生物制剂和个性化医学的关注。Bristol-Myers Squibb（美国）通过其近期收购战略定位，增强了其在免疫学领域的能力，并扩大了其银屑病治疗选择。市场内的关键商业策略包括本地化制造和供应链优化，这对于满足不同地区患者的多样化需求至关重要。竞争结构似乎适度分散，几家主要参与者对市场动态施加影响。这种分散性允许多种治疗选择，促进公司之间的创新和竞争。这些主要参与者的集体影响力显著，因为他们推动了治疗效果和患者结果的进步。2025年10月，AbbVie（美国）宣布与一家领先的远程医疗提供商建立战略合作伙伴关系，以增强患者对其银屑病治疗的获取。这一合作旨在将数字健康解决方案整合到治疗路径中，可能改善患者的依从性和结果。这一举措的战略重要性在于AbbVie认识到远程医疗在慢性病管理中的日益重要性，定位自己为患者参与的领导者。2025年9月，Amgen（美国）启动了一项新的临床试验，针对其创新的银屑病疗法，该疗法利用了一种新机制。该试验旨在评估该治疗在不同患者群体中的长期疗效和安全性。这一举措的重要性在于Amgen对推进个性化医学的承诺，这可能导致针对个别患者需求的改善治疗选择。2025年8月，Bristol-Myers Squibb（美国）完成了对一家专注于自体免疫疾病下一代生物制剂的生物技术公司的收购。这一收购预计将增强Bristol-Myers Squibb的产品线，并提升其在银屑病治疗市场的竞争优势。这一举措的战略重要性反映了行业内整合的更广泛趋势，因为公司寻求扩大其治疗产品并加速创新。截至2025年11月，银屑病治疗市场的当前竞争趋势越来越受到数字化、可持续性和人工智能（AI）在药物开发中的整合的定义。战略联盟变得越来越普遍，因为公司认识到合作在增强其能力和市场覆盖范围方面的价值。展望未来，竞争差异化可能会发展，从传统的基于价格的竞争转向关注创新、技术进步和供应链可靠性。这一转变可能最终导致改善患者结果和更可持续的市场环境。

## Recent News & Developments

在美国银屑病治疗市场的最新发展中，主要参与者如诺华和AbbVie推出了升级配方，这些配方在临床试验中显示出更好的疗效。例如，AbbVie的药物Humira继续主导市场，而新的参与者紧随其后。此外，在2023年9月，Regeneron制药宣布与赛诺菲建立战略合作伙伴关系，以增强其湿疹和银屑病疗法的交付，展示了领先公司之间的合作。

当前的事务反映出消费者对个性化医学的需求日益增长，促使像礼来和Amgen这样的公司在生物治疗的研发上进行大量投资。

在并购新闻中，Bristol Myers Squibb于2023年10月完成了对Myokardia的收购，旨在扩大其心血管产品组合，这可能间接影响其银屑病产品战略。市场估值稳步增长，预计到2025年美国银屑病治疗市场将达到120亿美元，主要受到创新药物和疾病控制与预防中心（CDC）报告的发病率增加的推动。这一增长突显了一个不断发展的格局，为既有公司和新进入银屑病治疗领域的公司提供了有希望的机会。

## Report Scope

| 市场规模 2024 | 1564.5（百万美元） |
| --- | --- |
| 市场规模 2025 | 1633.81（百万美元） |
| 市场规模 2035 | 2520.0（百万美元） |
| 年均复合增长率（CAGR） | 4.43%（2025 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 百万美元 |
| 关键公司简介 | AbbVie（美国）、Amgen（美国）、Bristol-Myers Squibb（美国）、Johnson & Johnson（美国）、诺华（瑞士）、辉瑞（美国）、Regeneron制药（美国）、UCB（比利时） |
| 覆盖的细分市场 | 类型、给药途径、适应症、最终用户 |
| 关键市场机会 | 生物制剂和个性化疗法的出现增强了银屑病治疗市场的治疗选择。 |
| 关键市场动态 | 对生物制剂的需求上升推动了银屑病治疗市场的创新和竞争。 |
| 覆盖的国家 | 美国 |

## Frequently Asked Questions

**Q: 2024年美国银屑病治疗市场的整体市场估值是多少？**
A: 整体市场估值在2024年为1564.5百万美元。

**Q: 到2035年，美国银屑病治疗市场的预计市场估值是多少？**
A: 2035年的预计估值为2520.0百万美元。

**Q: 在2025年至2035年的预测期内，美国银屑病治疗市场的预期年均增长率（CAGR）是多少？**
A: 在2025年至2035年的预测期内，预期年均增长率为4.43%。

**Q: 哪些公司被认为是美国银屑病治疗市场的关键参与者？**
A: 关键参与者包括AbbVie、Amgen、百时美施贵宝、强生、诺华、辉瑞、Regeneron制药和UCB。

**Q: 2024年美国银屑病治疗市场生物制剂的估值是多少？**
A: 生物制剂的估值在2024年为614.5百万美元，预计到2035年将达到1000.0百万美元。

**Q: 局部治疗与系统治疗在市场估值方面有何比较？**
A: 局部治疗在2024年的估值为300.0百万美元，而系统治疗的估值为450.0百万美元。

**Q: 2024年斑块型银屑病治疗的市场估值是多少？**
A: 斑块型银屑病治疗的市场估值在2024年为800.0百万美元，预计到2035年将达到1300.0百万美元。

**Q: 2024年美国银屑病治疗市场中哪个细分市场的估值最高？**
A: 生物制剂在2024年的估值最高，达到614.5百万美元。

**Q: 到2035年，注射治疗的预计估值是多少？**
A: 注射治疗的预计估值预计到2035年将达到800.0百万美元。

**Q: 2024年哪个最终用户细分市场的估值最高？**
A: 医院细分市场在2024年的估值最高，达到600.0百万美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-psoriasis-treatment-market-15827*